I follow PATH and I missed the news this am, thanks for posting (been on vacation etc). This has been a good buy when it drops below $3/share. The PDUFA date for the migraine patch using sumitriptan is around Jan 10, 2013. The company replaced its CEO about a couple months back, Jane Hollingsworth. They missed their guidance on their promised resubmission date. I had been buying in the low $3s and selling in the $4s.
I think the patch has potential, and this minnow has a market cap of around $45M. Dunno about how well the resubmission was crafted, and they had to re-design their patch system to make dosing a bit easier and more clear to the migraineur, and they did a subsequent PK study. Not much of anything in their pipe beyond this migraine drug.
I do not hold any shares currently.
Have not been on this board lately as toooooo much time has been wasted on PPHM. And it is still going on.
